{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T01:34:33Z","timestamp":1793237673452,"version":"4.5.0"},"reference-count":115,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,17]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>HIV infection increases cancer risk and is linked to cancers associated to infectious agents classified as carcinogenic to humans by the International Agency for Research on Cancer. Lymphomas represent one of the most frequent malignancies among individuals infected by HIV. Diffuse large B-cell lymphoma remains a leading cancer after the introduction of combined antiretroviral therapy (cART). The incidence of other lymphomas including Burkitt lymphoma, primary effusion lymphomas, and plasmablastic lymphoma of the oral cavity remain stable, whereas the incidence of Hodgkin lymphoma and Kaposi sarcoma-associated herpesvirus\u00a0(KSHV)-associated multicentric Castleman disease has increased. The heterogeneity of lymphomas in individuals infected by HIV likely depends on the complexity of involved pathogenetic mechanisms (ie, HIV-induced immunosuppression, genetic abnormalities,\u00a0cytokine dysregulation, and coinfection with the gammaherpesviruses Epstein-Barr virus and KSHV) and the dysregulation of the immune responses controlling these viruses. In the modern cART era, standard treatments for HIV-associated lymphoma including stem cell transplantation in relapsed\/refractory disease mirror that of the general population. The combination of cART and antineoplastic treatments has resulted in remarkable prolongation of long-term survival. However, oncolytic and immunotherapic strategies and therapies targeting specific viral oncogenes will need to be developed.<\/jats:p>","DOI":"10.1182\/blood.2020005469","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T20:18:26Z","timestamp":1630527506000},"page":"995-1012","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":125,"title":["Hematologic cancers in individuals infected by HIV"],"prefix":"10.1182","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2211-639X","authenticated-orcid":false,"given":"Antonino","family":"Carbone","sequence":"first","affiliation":[{"name":"Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, National Cancer Institute, Aviano, Italy;"},{"name":"\u201cS. Maria degli Angeli\u201d Hospital, Pordenone, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3386-5142","authenticated-orcid":false,"given":"Emanuela","family":"Vaccher","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Tumors Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Aviano, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7226-1942","authenticated-orcid":false,"given":"Annunziata","family":"Gloghini","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2022021716211811400_B1","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: a review and synthetic analysis","volume":"13","author":"de Martel","year":"2012","journal-title":"Lancet Oncol."},{"issue":"25","key":"2022021716211811400_B2","first-page":"305","article-title":"Kaposi\u2019s sarcoma and Pneumocystis pneumonia among homosexual men: New York City and California","volume":"30","author":"Centers for Disease Control (CDC)","year":"1981","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"9581","key":"2022021716211811400_B3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet."},{"issue":"2","key":"2022021716211811400_B4","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/QAD.0b013e3282f2705d","article-title":"Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy","volume":"22","author":"Polesel","year":"2008","journal-title":"AIDS."},{"issue":"5","key":"2022021716211811400_B5","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/cncr.25547","article-title":"Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States","volume":"117","author":"Simard","year":"2011","journal-title":"Cancer."},{"issue":"6","key":"2022021716211811400_B6","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/1055-9965.EPI-13-0040","article-title":"The epidemic of non-Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992-2009","volume":"22","author":"Shiels","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"2022021716211811400_B7","volume-title":"Human Immunodeficiency Viruses and Human T-Cell Lymphotropic Viruses","author":"International Agency for Research and Cancer (IARC)","year":"1996"},{"key":"2022021716211811400_B8","volume":"vol. 100","author":"International Agency for Research and Cancer (IARC)","year":"2012","journal-title":"A Review of Human Carcinogens. Part B: Biological Agents"},{"issue":"46","key":"2022021716211811400_B9","doi-asserted-by":"crossref","first-page":"14331","DOI":"10.1073\/pnas.1514748112","article-title":"Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis","volume":"112","author":"Dolcetti","year":"2015","journal-title":"Proc Natl Acad Sci USA."},{"issue":"11","key":"2022021716211811400_B10","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2015-11-681411","article-title":"A lymphomagenic role for HIV beyond immune suppression?","volume":"127","author":"Dolcetti","year":"2016","journal-title":"Blood."},{"issue":"17","key":"2022021716211811400_B11","first-page":"1","article-title":"1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults","volume":"41","year":"1992","journal-title":"MMWR Recomm Rep."},{"issue":"10","key":"2022021716211811400_B12","first-page":"1","article-title":"Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged &lt;18 months and for HIV infection and AIDS among children aged 18 months to &lt;13 years\u2013United States, 2008","volume":"57","author":"Schneider","year":"2008","journal-title":"MMWR Recomm Rep."},{"issue":"18","key":"2022021716211811400_B13","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199505043321802","article-title":"Kaposi\u2019s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas","volume":"332","author":"Cesarman","year":"1995","journal-title":"N Engl J Med."},{"issue":"7","key":"2022021716211811400_B14","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood.V99.7.2331","article-title":"High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease","volume":"99","author":"Oksenhendler","year":"2002","journal-title":"Blood."},{"issue":"4","key":"2022021716211811400_B15","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","article-title":"Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection","volume":"89","author":"Delecluse","year":"1997","journal-title":"Blood."},{"key":"2022021716211811400_B16","first-page":"449","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.","author":"Said","year":"2017"},{"issue":"11","key":"2022021716211811400_B17","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJMra1615896","article-title":"HIV-associated cancers and related diseases","volume":"378","author":"Yarchoan","year":"2018","journal-title":"N Engl J Med."},{"issue":"4","key":"2022021716211811400_B18","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrclinonc.2014.31","article-title":"Diagnosis and management of lymphomas and other cancers in HIV-infected patients","volume":"11","author":"Carbone","year":"2014","journal-title":"Nat Rev Clin Oncol."},{"issue":"3","key":"2022021716211811400_B19","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/sj.bjc.6605756","article-title":"Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study","volume":"103","author":"Franceschi","year":"2010","journal-title":"Br J Cancer."},{"issue":"9","key":"2022021716211811400_B20","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jnci\/djr076","article-title":"Cancer burden in the HIV-infected population in the United States","volume":"103","author":"Shiels","year":"2011","journal-title":"J Natl Cancer Inst."},{"issue":"11","key":"2022021716211811400_B21","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1093\/cid\/cit497","article-title":"Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort","volume":"57","author":"Hleyhel","year":"2013","journal-title":"Clin Infect Dis."},{"issue":"11","key":"2022021716211811400_B22","doi-asserted-by":"crossref","first-page":"e495","DOI":"10.1016\/S2352-3018(17)30125-X","article-title":"Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study","volume":"4","author":"Hern\u00e1ndez-Ram\u00edrez","year":"2017","journal-title":"Lancet HIV."},{"issue":"18","key":"2022021716211811400_B23","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1097\/QAD.0000000000002003","article-title":"Non-Hodgkin lymphoma risk in adults living with HIV across five continents","volume":"32","author":"AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord","year":"2018","journal-title":"AIDS."},{"issue":"5","key":"2022021716211811400_B24","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/sj.bjc.6604923","article-title":"Pattern of cancer risk in persons with AIDS in Italy in the HAART era","volume":"100","author":"Dal Maso","year":"2009","journal-title":"Br J Cancer."},{"issue":"16","key":"2022021716211811400_B25","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jnci\/djt158","article-title":"Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era","volume":"105","author":"Gopal","year":"2013","journal-title":"J Natl Cancer Inst."},{"issue":"2","key":"2022021716211811400_B26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/QAI.0000000000000946","article-title":"Evolution of HIV-associated lymphoma over 3 decades","volume":"72","author":"Ramaswami","year":"2016","journal-title":"J Acquir Immune Defic Syndr."},{"key":"2022021716211811400_B27","first-page":"143","volume-title":"Cancer Med.","author":"Ota","year":"2014"},{"issue":"20","key":"2022021716211811400_B28","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1182\/blood-2014-11-599951","article-title":"The tumor virus landscape of AIDS-related lymphomas","volume":"125","author":"Arvey","year":"2015","journal-title":"Blood."},{"key":"2022021716211811400_B29","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.semcancer.2015.06.002","article-title":"Microenvironment and HIV-related lymphomagenesis","volume":"34","author":"Pantanowitz","year":"2015","journal-title":"Semin Cancer Biol."},{"issue":"11","key":"2022021716211811400_B30","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1038\/leu.2017.106","article-title":"HIV Tat induces a prolonged MYC relocalization next to IGH in circulating B-cells","volume":"31","author":"Germini","year":"2017","journal-title":"Leukemia."},{"issue":"6","key":"2022021716211811400_B31","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1182\/blood-2008-09-180315","article-title":"HIV-associated lymphomas and gamma-herpesviruses","volume":"113","author":"Carbone","year":"2009","journal-title":"Blood."},{"key":"2022021716211811400_B32","doi-asserted-by":"crossref","DOI":"10.55418\/9781933477381","volume-title":"Tumors of the Lymph Nodes and Spleen","author":"Medeiros","year":"2017"},{"issue":"1","key":"2022021716211811400_B33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/(SICI)1098-2264(199901)24:1<16::AID-GCC3>3.0.CO;2-F","article-title":"Genetic characterization of HHV-8\/KSHV-positive primary effusion lymphoma reveals frequent mutations of BCL6: implications for disease pathogenesis and histogenesis","volume":"24","author":"Gaidano","year":"1999","journal-title":"Genes Chromosomes Cancer."},{"issue":"1","key":"2022021716211811400_B34","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2643-3230.BCD-20-0051","article-title":"Genomic characterization of HIV-associated plasmablastic lymphoma identifies pervasive mutations in the JAK-STAT pathway","volume":"1","author":"Liu","year":"2020","journal-title":"Blood Cancer Discov."},{"issue":"6","key":"2022021716211811400_B35","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/ijc.30473","article-title":"The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis","volume":"140","author":"Carbone","year":"2017","journal-title":"Int J Cancer."},{"issue":"6","key":"2022021716211811400_B36","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"2","key":"2022021716211811400_B37","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/ijc.28923","article-title":"KSHV-associated multicentric Castleman disease: a tangle of different entities requiring multitarget treatment strategies","volume":"137","author":"Carbone","year":"2015","journal-title":"Int J Cancer."},{"issue":"4","key":"2022021716211811400_B38","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.V86.4.1276.bloodjournal8641276","article-title":"Kaposi\u2019s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman\u2019s disease","volume":"86","author":"Soulier","year":"1995","journal-title":"Blood."},{"issue":"6","key":"2022021716211811400_B39","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/civ996","article-title":"Clinical features and outcomes of patients with symptomatic kaposi sarcoma herpesvirus (KSHV)-associated inflammation: prospective characterization of KSHV inflammatory cytokine syndrome (KICS)","volume":"62","author":"Polizzotto","year":"2016","journal-title":"Clin Infect Dis."},{"key":"2022021716211811400_B40","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fmicb.2012.00073","article-title":"Clinical manifestations of kaposi sarcoma herpesvirus lytic activation: multicentric Castleman disease (KSHV-MCD) and the KSHV inflammatory cytokine syndrome","volume":"3","author":"Polizzotto","year":"2012","journal-title":"Front Microbiol."},{"issue":"26","key":"2022021716211811400_B41","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1182\/blood-2013-08-519959","article-title":"Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease","volume":"122","author":"Polizzotto","year":"2013","journal-title":"Blood."},{"issue":"6769","key":"2022021716211811400_B42","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature."},{"issue":"5","key":"2022021716211811400_B43","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes [corrections published in Nat Med. 2018;24:1292 and Nat Med. 2018;24:1290-1291]","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med."},{"issue":"4","key":"2022021716211811400_B44","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell."},{"issue":"5","key":"2022021716211811400_B45","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2004-12-4631","article-title":"AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping","volume":"106","author":"Hoffmann","year":"2005","journal-title":"Blood."},{"issue":"30","key":"2022021716211811400_B46","doi-asserted-by":"crossref","first-page":"5039","DOI":"10.1200\/JCO.2008.20.5450","article-title":"Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034","volume":"27","author":"Chadburn","year":"2009","journal-title":"J Clin Oncol."},{"issue":"15","key":"2022021716211811400_B47","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood-2009-11-253039","article-title":"The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma","volume":"115","author":"Dunleavy","year":"2010","journal-title":"Blood."},{"issue":"4","key":"2022021716211811400_B48","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/10428194.2018.1512711","article-title":"Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma","volume":"60","author":"Baptista","year":"2019","journal-title":"Leuk Lymphoma."},{"issue":"17","key":"2022021716211811400_B49","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1182\/blood-2018-01-791400","article-title":"Optimizing treatment of HIV-associated lymphoma","volume":"134","author":"Noy","year":"2019","journal-title":"Blood."},{"issue":"5","key":"2022021716211811400_B50","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdv036","article-title":"Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma","volume":"26","author":"Barta","year":"2015","journal-title":"Ann Oncol."},{"issue":"1","key":"2022021716211811400_B51","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/COH.0000000000000320","article-title":"Cancer care disparities in people with HIV in the United States","volume":"12","author":"Suneja","year":"2017","journal-title":"Curr Opin HIV AIDS."},{"issue":"3","key":"2022021716211811400_B52","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1158\/1055-9965.EPI-16-0595","article-title":"HIV infection and survival of lymphoma patients in the era of highly active antiretroviral therapy","volume":"26","author":"Han","year":"2017","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"issue":"11","key":"2022021716211811400_B53","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1002\/ijc.32895","article-title":"Cause-specific mortality after diagnosis of cancer among HIV-positive patients: a collaborative analysis of cohort studies","volume":"146","author":"Trickey","year":"2020","journal-title":"Int J Cancer."},{"issue":"5","key":"2022021716211811400_B54","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood-2004-08-3300","article-title":"Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials","volume":"105","author":"Spina","year":"2005","journal-title":"Blood."},{"issue":"14","key":"2022021716211811400_B55","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood-2011-08-373738","article-title":"How I treat HIV-associated lymphoma","volume":"119","author":"Dunleavy","year":"2012","journal-title":"Blood."},{"issue":"5","key":"2022021716211811400_B56","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood."},{"issue":"25","key":"2022021716211811400_B57","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2005.05.4684","article-title":"Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin\u2019s lymphoma","volume":"24","author":"Bou\u00e9","year":"2006","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022021716211811400_B58","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1365-2141.2012.09046.x","article-title":"Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP","volume":"157","author":"Ribera","year":"2012","journal-title":"Br J Haematol."},{"issue":"15","key":"2022021716211811400_B59","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2009-08-231613","article-title":"Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma","volume":"115","author":"Sparano","year":"2010","journal-title":"Blood."},{"issue":"16","key":"2022021716211811400_B60","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1002\/cncr.26723","article-title":"Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma","volume":"118","author":"Barta","year":"2012","journal-title":"Cancer."},{"issue":"19","key":"2022021716211811400_B61","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","article-title":"Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients","volume":"122","author":"Barta","year":"2013","journal-title":"Blood."},{"issue":"4","key":"2022021716211811400_B62","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/QAD.0b013e32834f30fa","article-title":"Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients","volume":"26","author":"Wyen","year":"2012","journal-title":"AIDS."},{"issue":"24","key":"2022021716211811400_B63","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1182\/blood-2014-07-586800","article-title":"Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease","volume":"124","author":"Uldrick","year":"2014","journal-title":"Blood."},{"issue":"8","key":"2022021716211811400_B64","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1200\/JCO.2004.08.195","article-title":"Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin\u2019s lymphoma: an Eastern Cooperative Oncology Group Trial (E1494)","volume":"22","author":"Sparano","year":"2004","journal-title":"J Clin Oncol."},{"issue":"21","key":"2022021716211811400_B65","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1200\/JCO.2000.18.21.3633","article-title":"Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH","volume":"18","author":"Gutierrez","year":"2000","journal-title":"J Clin Oncol."},{"issue":"21","key":"2022021716211811400_B66","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III Intergroup Trial Alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol."},{"issue":"2","key":"2022021716211811400_B67","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood-2015-01-623900","article-title":"AMC 048: modified CODOX-M\/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma","volume":"126","author":"Noy","year":"2015","journal-title":"Blood."},{"issue":"8","key":"2022021716211811400_B68","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/QAD.0000000000000623","article-title":"Adding rituximab to CODOX-M\/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy","volume":"29","author":"Alwan","year":"2015","journal-title":"AIDS."},{"issue":"22","key":"2022021716211811400_B69","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1200\/JCO.20.00303","article-title":"Multicenter study of risk-adapted therapy with dose-adjusted EPOCH-R in adults with untreated Burkitt lymphoma","volume":"38","author":"Roschewski","year":"2020","journal-title":"J Clin Oncol."},{"issue":"15","key":"2022021716211811400_B70","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2014-10-567479","article-title":"The biology and treatment of plasmablastic lymphoma","volume":"125","author":"Castillo","year":"2015","journal-title":"Blood."},{"issue":"4","key":"2022021716211811400_B71","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bjh.15156","article-title":"Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma","volume":"184","author":"Castillo","year":"2019","journal-title":"Br J Haematol."},{"issue":"16","key":"2022021716211811400_B72","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2019-01-893339","article-title":"Viral, immunologic, and clinical features of primary effusion lymphoma","volume":"133","author":"Lurain","year":"2019","journal-title":"Blood."},{"issue":"11","key":"2022021716211811400_B73","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood.2019003959","article-title":"Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)","volume":"136","author":"Ramos","year":"2020","journal-title":"Blood."},{"issue":"17","key":"2022021716211811400_B74","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1002\/cncr.30112","article-title":"Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: analysis of the National Cancer Data Base","volume":"122","author":"Olszewski","year":"2016","journal-title":"Cancer."},{"issue":"1","key":"2022021716211811400_B75","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/neuonc\/now155","article-title":"Long-term survival in AIDS-related primary central nervous system lymphoma","volume":"19","author":"Gupta","year":"2017","journal-title":"Neuro-oncol."},{"issue":"8","key":"2022021716211811400_B76","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1212\/WNL.0000000000004265","article-title":"Long-term AIDS-related PCNSL outcomes with HD-MTX and combined antiretroviral therapy","volume":"89","author":"Moulignier","year":"2017","journal-title":"Neurology."},{"issue":"19","key":"2022021716211811400_B77","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1182\/blood.2020006048","article-title":"Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate","volume":"136","author":"Lurain","year":"2020","journal-title":"Blood."},{"issue":"9","key":"2022021716211811400_B78","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S1470-2045(11)70056-0","article-title":"Use of antineoplastic agents in patients with cancer who have HIV\/AIDS","volume":"12","author":"Rudek","year":"2011","journal-title":"Lancet Oncol."},{"issue":"8","key":"2022021716211811400_B79","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1080\/10428194.2017.1403597","article-title":"Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034","volume":"59","author":"Tan","year":"2018","journal-title":"Leuk Lymphoma."},{"issue":"23","key":"2022021716211811400_B80","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1200\/JCO.2003.06.039","article-title":"High-dose therapy and autologous peripheral-blood stem-cell transplantation as salvage treatment for HIV-associated lymphoma in patients receiving highly active antiretroviral therapy","volume":"21","author":"Re","year":"2003","journal-title":"J Clin Oncol."},{"issue":"8","key":"2022021716211811400_B81","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood-2015-08-664706","article-title":"Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803\/AMC 071 trial","volume":"128","author":"Alvarnas","year":"2016","journal-title":"Blood."},{"issue":"9","key":"2022021716211811400_B82","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.bbmt.2010.03.019","article-title":"HIV status does not affect the outcome of autologous stem cell transplantation (ASCT) for non-Hodgkin lymphoma (NHL)","volume":"16","author":"Krishnan","year":"2010","journal-title":"Biol Blood Marrow Transplant."},{"issue":"17","key":"2022021716211811400_B83","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1097\/QAD.0000000000000851","article-title":"Postautologous stem cell transplantation long-term outcomes in 26 HIV-positive patients affected by relapsed\/refractory lymphoma","volume":"29","author":"Zanet","year":"2015","journal-title":"AIDS."},{"issue":"11","key":"2022021716211811400_B84","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.bbmt.2019.06.033","article-title":"Allogeneic hematopoietic cell transplant for HIV patients with hematologic malignancies: the BMT CTN-0903\/AMC-080 trial","volume":"25","author":"Ambinder","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"9","key":"2022021716211811400_B85","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1097\/QAD.0000000000002209","article-title":"Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders","volume":"33","author":"Kwon","year":"2019","journal-title":"AIDS."},{"issue":"10","key":"2022021716211811400_B86","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2010-09-309591","article-title":"Evidence for the cure of HIV infection by CCR5\u039432\/\u039432 stem cell transplantation","volume":"117","author":"Allers","year":"2011","journal-title":"Blood."},{"issue":"7751","key":"2022021716211811400_B87","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","article-title":"HIV-1 remission following CCR5\u039432\/\u039432 haematopoietic stem-cell transplantation","volume":"568","author":"Gupta","year":"2019","journal-title":"Nature."},{"issue":"5","key":"2022021716211811400_B88","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/CCO.0b013e3283560697","article-title":"Impact of highly effective antiretroviral therapy on the risk for Hodgkin lymphoma among people with human immunodeficiency virus infection","volume":"24","author":"Goedert","year":"2012","journal-title":"Curr Opin Oncol."},{"issue":"10","key":"2022021716211811400_B89","doi-asserted-by":"crossref","first-page":"e77409","DOI":"10.1371\/journal.pone.0077409","article-title":"Effect of immune reconstitution on the incidence of HIV-related Hodgkin lymphoma [correction published in PLoS One. 2013;8(10);e77409]","volume":"8","author":"Kowalkowski","year":"2013","journal-title":"PLoS One."},{"issue":"1","key":"2022021716211811400_B90","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2011-02-339275","article-title":"HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy","volume":"118","author":"Lanoy","year":"2011","journal-title":"Blood."},{"issue":"1","key":"2022021716211811400_B91","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-020-0189-6","article-title":"Hodgkin lymphoma","volume":"6","author":"Connors","year":"2020","journal-title":"Nat Rev Dis Primers."},{"issue":"12","key":"2022021716211811400_B92","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1182\/blood-2006-05-024109","article-title":"Hodgkin lymphoma and immunodeficiency in persons with HIV\/AIDS","volume":"108","author":"Biggar","year":"2006","journal-title":"Blood."},{"issue":"2","key":"2022021716211811400_B93","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3324\/haematol.10479","article-title":"Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin\u2019s lymphoma","volume":"92","author":"Xicoy","year":"2007","journal-title":"Haematologica."},{"issue":"33","key":"2022021716211811400_B94","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1200\/JCO.2011.41.4193","article-title":"HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era","volume":"30","author":"Montoto","year":"2012","journal-title":"J Clin Oncol."},{"issue":"9","key":"2022021716211811400_B95","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1093\/cid\/civ627","article-title":"High risk features contrast with favorable outcomes in HIV-associated Hodgkin lymphoma in the modern cART era, ANRS CO16 LYMPHOVIR cohort","volume":"61","author":"Besson","year":"2015","journal-title":"Clin Infect Dis."},{"issue":"5","key":"2022021716211811400_B96","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/QAD.0000000000000986","article-title":"Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy","volume":"30","author":"Olszewski","year":"2016","journal-title":"AIDS."},{"issue":"8","key":"2022021716211811400_B97","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2014-08-551598","article-title":"How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus","volume":"125","author":"Uldrick","year":"2015","journal-title":"Blood."},{"issue":"33","key":"2022021716211811400_B98","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2012.41.8137","article-title":"Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study","volume":"30","author":"Hentrich","year":"2012","journal-title":"J Clin Oncol."},{"issue":"2","key":"2022021716211811400_B99","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/10428194.2016.1201573","article-title":"Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial","volume":"58","author":"Danilov","year":"2017","journal-title":"Leuk Lymphoma."},{"issue":"5","key":"2022021716211811400_B100","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/QAD.0000000000001729","article-title":"Brentuximab vedotin with AVD shows safety, in the absence of strong CYP3A4 inhibitors, in newly diagnosed HIV-associated Hodgkin lymphoma","volume":"32","author":"Rubinstein","year":"2018","journal-title":"AIDS."},{"issue":"9","key":"2022021716211811400_B101","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer: a phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol."},{"issue":"4","key":"2022021716211811400_B102","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/annonc\/mdn697","article-title":"The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman\u2019s disease","volume":"20","author":"Powles","year":"2009","journal-title":"Ann Oncol."},{"issue":"1","key":"2022021716211811400_B103","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.hoc.2017.09.007","article-title":"Treatment of Kaposi sarcoma herpesvirus-associated multicentric Castleman disease","volume":"32","author":"Lurain","year":"2018","journal-title":"Hematol Oncol Clin North Am."},{"issue":"5","key":"2022021716211811400_B104","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/CCO.0b013e328355e0f3","article-title":"Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease","volume":"24","author":"Uldrick","year":"2012","journal-title":"Curr Opin Oncol."},{"issue":"12","key":"2022021716211811400_B105","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/0003-4819-147-12-200712180-00003","article-title":"Brief communication: rituximab in HIV-associated multicentric Castleman disease","volume":"147","author":"Bower","year":"2007","journal-title":"Ann Intern Med."},{"issue":"10","key":"2022021716211811400_B106","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood-2011-08-376012","article-title":"Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease","volume":"119","author":"G\u00e9rard","year":"2012","journal-title":"Blood."},{"issue":"12","key":"2022021716211811400_B107","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/cid\/ciw621","article-title":"Immediate antiretroviral therapy reduces risk of infection-related cancer during early HIV infection","volume":"63","author":"Borges","year":"2016","journal-title":"Clin Infect Dis."},{"issue":"9","key":"2022021716211811400_B108","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/QAD.0b013e32835f6b0c","article-title":"Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers","volume":"27","author":"Borges","year":"2013","journal-title":"AIDS."},{"issue":"9","key":"2022021716211811400_B109","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of antiretroviral therapy in early asymptomatic HIV infection","volume":"373","author":"Lundgren","year":"2015","journal-title":"N Engl J Med."},{"issue":"11","key":"2022021716211811400_B110","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.1016\/S2352-3018(18)30179-6","article-title":"Incidence of first and second primary cancers diagnosed among people with HIV, 1985-2013: a population-based, registry linkage study","volume":"5","author":"Hessol","year":"2018","journal-title":"Lancet HIV."},{"issue":"8","key":"2022021716211811400_B111","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/QAD.0000000000002528","article-title":"Cancer risk following lymphoid malignancies among HIV-infected people","volume":"34","author":"Mahale","year":"2020","journal-title":"AIDS."},{"issue":"11","key":"2022021716211811400_B112","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1158\/1535-7163.MCT-17-0041","article-title":"Oncolytic reactivation of KSHV as a therapeutic approach for primary effusion lymphoma","volume":"16","author":"Zhou","year":"2017","journal-title":"Mol Cancer Ther."},{"issue":"7","key":"2022021716211811400_B113","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMc1806295","article-title":"Daratumumab in primary effusion lymphoma","volume":"379","author":"Shah","year":"2018","journal-title":"N Engl J Med."},{"issue":"1","key":"2022021716211811400_B114","doi-asserted-by":"crossref","first-page":"e02871","DOI":"10.1128\/mBio.02871-18","article-title":"Targeting mTOR with MLN0128 overcomes rapamycin and chemoresistant primary effusion lymphoma","volume":"10","author":"Caro-Vegas","year":"2019","journal-title":"mBio."},{"issue":"12","key":"2022021716211811400_B115","doi-asserted-by":"crossref","first-page":"E1527","DOI":"10.3390\/cells8121527","article-title":"CD38, a receptor with multifunctional activities: from modulatory functions on regulatory cell subsets and extracellular vesicles, to a target for therapeutic strategies","volume":"8","author":"Morandi","year":"2019","journal-title":"Cells."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/7\/995\/1872879\/bloodbld2020005469c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/7\/995\/1872879\/bloodbld2020005469c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T12:38:41Z","timestamp":1673181521000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/7\/995\/476746\/Hematologic-cancers-in-individuals-infected-by-HIV"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":115,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,2,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020005469","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]}}}